SG10202009484WA - Preparation containing tetracyclic compound at high dose - Google Patents
Preparation containing tetracyclic compound at high doseInfo
- Publication number
- SG10202009484WA SG10202009484WA SG10202009484WA SG10202009484WA SG10202009484WA SG 10202009484W A SG10202009484W A SG 10202009484WA SG 10202009484W A SG10202009484W A SG 10202009484WA SG 10202009484W A SG10202009484W A SG 10202009484WA SG 10202009484W A SG10202009484W A SG 10202009484WA
- Authority
- SG
- Singapore
- Prior art keywords
- high dose
- preparation containing
- tetracyclic compound
- containing tetracyclic
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014092101 | 2014-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202009484WA true SG10202009484WA (en) | 2020-11-27 |
Family
ID=54332608
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607623XA SG11201607623XA (en) | 2014-04-25 | 2015-04-24 | Preparation containing tetracyclic compound at high dose |
| SG10202009484WA SG10202009484WA (en) | 2014-04-25 | 2015-04-24 | Preparation containing tetracyclic compound at high dose |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201607623XA SG11201607623XA (en) | 2014-04-25 | 2015-04-24 | Preparation containing tetracyclic compound at high dose |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10350214B2 (en) |
| EP (2) | EP3135287A4 (en) |
| JP (2) | JP5859712B1 (en) |
| KR (2) | KR102478887B1 (en) |
| CN (2) | CN106456651A (en) |
| AR (1) | AR100187A1 (en) |
| AU (2) | AU2015250574B2 (en) |
| BR (1) | BR112016021206B1 (en) |
| CA (2) | CA3140565C (en) |
| IL (2) | IL248363B (en) |
| MX (2) | MX2016013809A (en) |
| MY (1) | MY189913A (en) |
| RU (2) | RU2020119391A (en) |
| SG (2) | SG11201607623XA (en) |
| TW (3) | TWI771839B (en) |
| WO (1) | WO2015163448A1 (en) |
| ZA (1) | ZA201606447B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2975024T (en) * | 2009-06-10 | 2018-05-14 | Chugai Pharmaceutical Co Ltd | Tetracyclic compounds |
| EP3698788A1 (en) | 2010-08-20 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Composition comprising tetracyclic compound |
| HUE040055T2 (en) | 2012-09-25 | 2019-02-28 | Chugai Pharmaceutical Co Ltd | Ret inhibitor |
| TR201907147T4 (en) | 2013-07-18 | 2019-06-21 | Taiho Pharmaceutical Co Ltd | Anti-tumor drug for intermittent administration of the Fgfr inhibitor. |
| EP3023101B1 (en) | 2013-07-18 | 2020-08-19 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for fgfr inhibitor-resistant cancer |
| WO2015163448A1 (en) | 2014-04-25 | 2015-10-29 | 中外製薬株式会社 | Preparation containing tetracyclic compound at high dose |
| TWI765410B (en) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | Use of amorphous body of tetracyclic compound |
| US11077093B2 (en) | 2015-01-16 | 2021-08-03 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
| AU2016240841C1 (en) | 2015-03-31 | 2018-05-17 | Taiho Pharmaceutical Co., Ltd. | Crystal of 3,5-disubstituted benzene alkynyl compound |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| AU2017226389B2 (en) | 2016-03-04 | 2023-02-02 | Taiho Pharmaceutical Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| RU2019138248A (en) | 2017-04-28 | 2021-05-28 | Астеллас Фарма Инк. | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION, CONTAINING ENZALUTAMIDE |
| PL3769765T3 (en) | 2018-03-19 | 2024-06-10 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
| MX2020014262A (en) * | 2018-06-29 | 2021-03-25 | Chugai Pharmaceutical Co Ltd | Pharmaceutical composition containing poorly-soluble basic medicine. |
| TWI825163B (en) | 2018-09-04 | 2023-12-11 | 日商中外製藥股份有限公司 | Method for producing tetracyclic compound |
| AR121187A1 (en) * | 2019-12-27 | 2022-04-27 | Chugai Pharmaceutical Co Ltd | METHOD TO CLASSIFY, EVALUATE OR MANUFACTURE SODIUM LAURYL SULFATE FROM RAW MATERIAL OR PHARMACEUTICAL FORMULATION CONTAINING IT |
| WO2021134647A1 (en) * | 2019-12-31 | 2021-07-08 | 广州帝奇医药技术有限公司 | Sustained release composition and preparation method therefor |
| CN116806152A (en) * | 2021-01-29 | 2023-09-26 | 中外制药株式会社 | Pharmaceutical composition for treating children cancer |
| CN118159274A (en) * | 2021-10-28 | 2024-06-07 | 中外制药株式会社 | Syrup preparation |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4918630B1 (en) | 1970-07-29 | 1974-05-11 | ||
| JPH0667840B2 (en) | 1988-11-30 | 1994-08-31 | 萬有製薬株式会社 | NB-818 easily absorbable formulation |
| US5028433A (en) | 1988-11-30 | 1991-07-02 | Banyu Pharmaceutical Co., Ltd. | Readily absorbable drug formulation of NB-818 |
| JPH0892090A (en) | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | Medicinal composition |
| DK0695755T3 (en) | 1994-08-04 | 1999-06-28 | Hoffmann La Roche | pyrrolocarbazoles |
| JPH09202728A (en) | 1995-12-11 | 1997-08-05 | Hisamitsu Pharmaceut Co Inc | Solid preparation |
| EA001450B1 (en) | 1996-05-01 | 2001-04-23 | Эли Лилли Энд Компани | Halo-substituted protein kinase c inhibitors |
| US6632822B1 (en) | 1999-05-14 | 2003-10-14 | The Australian National University | Compounds and therapeutic methods |
| CA2430288C (en) | 2000-12-01 | 2009-03-10 | Kyowa Hakko Kogyo Co., Ltd. | A composition improved in the solubility or oral absorbability |
| GB0030417D0 (en) | 2000-12-13 | 2001-01-24 | Pharma Mar Sa | An anticancer lead compound isolated from a New Zealand ascidian |
| FR2841138B1 (en) | 2002-06-25 | 2005-02-25 | Cll Pharma | SOLID PHARMACEUTICAL COMPOSITION COMPRISING A LIPOPHILIC ACTIVE INGREDIENT, ITS PREPARATION PROCESS |
| US7807197B2 (en) | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
| WO2005009398A2 (en) | 2003-02-28 | 2005-02-03 | Inotek Pharmaceuticals Corporation | Tetracyclic benzamide derivatives and methods of use thereof |
| ES2263862T3 (en) | 2003-03-07 | 2006-12-16 | Istituto Nazionale Per Lo Studio E La Cura Dei Tumori | ANAPLASIC LYMPHOMA KINASE TEST, ITS REAGENTS AND COMPOSITIONS. |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| CA2532800C (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
| US20070060595A1 (en) | 2003-10-10 | 2007-03-15 | Toshio Yoshizawa | Novel fused heterocyclic compound and use thereof |
| ES2308272T3 (en) | 2003-11-21 | 2008-12-01 | Novartis Ag | DERIVATIVES OF 1H-IMIDAZOQUINOLINE AS INHIBITORS OF PROTEIN QUINASA. |
| WO2005056529A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
| JP4927704B2 (en) | 2004-03-19 | 2012-05-09 | シュペーデル・エクスペリメンタ・アーゲー | Organic compounds |
| CA2559866A1 (en) | 2004-03-31 | 2005-10-20 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| ES2341351T3 (en) | 2004-08-26 | 2010-06-18 | Pfizer, Inc. | ENANTIOMERALLY PURE AMINOHETEROARILO COMPOUNDS AS PROTEIN CINASE INHIBITORS. |
| US7091202B2 (en) | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
| GB0423964D0 (en) * | 2004-10-28 | 2004-12-01 | Jagotec Ag | Dosage form |
| GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
| RU2008122547A (en) | 2005-11-07 | 2009-12-20 | Айрм Ллк (Bm) | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF ARPP (ACTIVATED RECEPTORS OF PROLIFERATOR PEROXIS) |
| AU2006323025B2 (en) | 2005-12-05 | 2012-07-05 | Pfizer Products Inc. | Polymorphs of a c-Met/HGFR inhibitor |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
| WO2008032767A1 (en) * | 2006-09-14 | 2008-03-20 | Astellas Pharma Inc. | Orally disintegrating tablet and process for production thereof |
| EP1914240B1 (en) | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
| CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| ES2633318T3 (en) | 2006-10-23 | 2017-09-20 | Cephalon, Inc. | Bicyclic derivatives fused 2,4-diaminopyrimidine as inhibitors of ALK and c-Met |
| EP2142551B1 (en) | 2007-04-17 | 2015-10-14 | Bristol-Myers Squibb Company | Fused heterocyclic 11-beta-hydroxysteroid dehydrogenase type i inhibitors |
| TWI389893B (en) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | Di (arylamino) ary1 compound |
| BRPI0814628B1 (en) | 2007-07-20 | 2022-04-05 | Nerviano Medical Sciences S.R.L. | Active substituted indazole derivatives as kinase inhibitors |
| JP5583592B2 (en) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | IDO inhibitor |
| US20090214648A1 (en) * | 2008-02-15 | 2009-08-27 | Malathi Kandakatla | Pharmaceutical formulations comprising ibuprofen and diphenhydramine |
| JP5554699B2 (en) | 2008-03-13 | 2014-07-23 | 第一三共株式会社 | Improving dissolution properties of formulations containing olmesartan medoxomil |
| US20100151034A1 (en) * | 2008-09-30 | 2010-06-17 | Astellas Pharma Inc. | Granular pharmaceutical composition of atorvastatin for oral administration |
| CA2759581A1 (en) | 2009-05-07 | 2010-11-11 | Astrazeneca Ab | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
| GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| PT2975024T (en) * | 2009-06-10 | 2018-05-14 | Chugai Pharmaceutical Co Ltd | Tetracyclic compounds |
| US20110311625A1 (en) * | 2010-06-14 | 2011-12-22 | Amruth Gowda Doddaveerappa | Solid dosage forms of fenofibrate |
| EP3698788A1 (en) * | 2010-08-20 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Composition comprising tetracyclic compound |
| TWI564008B (en) * | 2010-09-30 | 2017-01-01 | 鹽野義製藥股份有限公司 | Formulation for solubility enhancement of poorly soluble drugs |
| JP5006987B2 (en) | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | Medicine containing tetracyclic compound |
| MX343509B (en) * | 2011-04-06 | 2016-11-08 | Dow Global Technologies Llc | Process for producing cellulose derivatives of high bulk density and good flowability. |
| EA027748B1 (en) * | 2012-04-04 | 2017-08-31 | Тева Фармасьютикалз Интернэшнл Гмбх | Use of pridopidine in combination with tetrabenazine for treating movement disorders and obesity |
| HUE040055T2 (en) | 2012-09-25 | 2019-02-28 | Chugai Pharmaceutical Co Ltd | Ret inhibitor |
| CA2923667A1 (en) * | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
| WO2015163448A1 (en) * | 2014-04-25 | 2015-10-29 | 中外製薬株式会社 | Preparation containing tetracyclic compound at high dose |
| WO2015163447A1 (en) | 2014-04-25 | 2015-10-29 | 中外製薬株式会社 | Novel crystal of tetracyclic compound |
| BR112016024421A2 (en) | 2014-06-18 | 2017-08-15 | Chugai Pharmaceutical Co Ltd | pharmaceutical composition, capsule and use of pharmaceutical composition |
| TWI765410B (en) | 2014-08-08 | 2022-05-21 | 日商中外製藥股份有限公司 | Use of amorphous body of tetracyclic compound |
-
2015
- 2015-04-24 WO PCT/JP2015/062520 patent/WO2015163448A1/en active Application Filing
- 2015-04-24 AR ARP150101248A patent/AR100187A1/en not_active Application Discontinuation
- 2015-04-24 MY MYPI2016001752A patent/MY189913A/en unknown
- 2015-04-24 KR KR1020227020701A patent/KR102478887B1/en active IP Right Grant
- 2015-04-24 SG SG11201607623XA patent/SG11201607623XA/en unknown
- 2015-04-24 RU RU2020119391A patent/RU2020119391A/en unknown
- 2015-04-24 KR KR1020167031396A patent/KR102412321B1/en active IP Right Grant
- 2015-04-24 BR BR112016021206-1A patent/BR112016021206B1/en active IP Right Grant
- 2015-04-24 US US15/304,133 patent/US10350214B2/en active Active
- 2015-04-24 CA CA3140565A patent/CA3140565C/en active Active
- 2015-04-24 MX MX2016013809A patent/MX2016013809A/en unknown
- 2015-04-24 EP EP15783124.9A patent/EP3135287A4/en active Pending
- 2015-04-24 TW TW109145714A patent/TWI771839B/en active
- 2015-04-24 TW TW111104939A patent/TWI831128B/en active
- 2015-04-24 JP JP2015530792A patent/JP5859712B1/en active Active
- 2015-04-24 EP EP24171823.8A patent/EP4397659A3/en active Pending
- 2015-04-24 CN CN201580020724.5A patent/CN106456651A/en active Pending
- 2015-04-24 SG SG10202009484WA patent/SG10202009484WA/en unknown
- 2015-04-24 TW TW104113204A patent/TWI720943B/en active
- 2015-04-24 CA CA2946518A patent/CA2946518C/en active Active
- 2015-04-24 CN CN202111292754.5A patent/CN113975243A/en active Pending
- 2015-04-24 AU AU2015250574A patent/AU2015250574B2/en active Active
- 2015-04-24 RU RU2016145057A patent/RU2724056C2/en active
- 2015-12-16 JP JP2015244821A patent/JP6129942B2/en active Active
-
2016
- 2016-09-19 ZA ZA2016/06447A patent/ZA201606447B/en unknown
- 2016-10-13 IL IL248363A patent/IL248363B/en active IP Right Grant
- 2016-10-20 MX MX2021012300A patent/MX2021012300A/en unknown
-
2019
- 2019-07-11 US US16/508,760 patent/US11433076B2/en active Active
-
2020
- 2020-09-10 AU AU2020230293A patent/AU2020230293B2/en active Active
-
2021
- 2021-05-12 IL IL283152A patent/IL283152B2/en unknown
-
2022
- 2022-07-29 US US17/877,542 patent/US20220378800A1/en not_active Abandoned
- 2022-08-26 US US17/896,758 patent/US20230105990A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201606447B (en) | Preparation containing tetracyclic compound at high dose | |
| IL249181A0 (en) | Compound containing self-immolative group | |
| GB201419579D0 (en) | Pharmaceutical compound | |
| GB201414730D0 (en) | Pharmaceutical compound | |
| GB201509443D0 (en) | Seed preparation | |
| GB201402277D0 (en) | Pharmaceutical compounds | |
| IL246447B (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| GB201415569D0 (en) | Therapeutic Compounds | |
| PL3363428T3 (en) | Perfusion dosage form | |
| HK1256671A1 (en) | Spirocyclic compounds | |
| HUE039338T2 (en) | Scintillator | |
| GB201416273D0 (en) | Therapeutic compounds | |
| HK1232121A1 (en) | Fullerene compounds as antioxidant therapy | |
| IL249907A0 (en) | Tricyclic triazolic compounds | |
| SG11201702334SA (en) | External preparation composition containing s-flurbiprofen | |
| HK1219664A1 (en) | Dosage form containing fungal components | |
| ZA201500995B (en) | Low dose pharmaceutical composition | |
| HK1254378A1 (en) | [(2-ethoxy-5-trans-1-propen-1-yl)-phenoxyl]-terminated compounds | |
| ZA201800217B (en) | Novel dosage regimen tiacumicin compound | |
| GB201520189D0 (en) | Compound for use | |
| GB201419570D0 (en) | Pharmaceutical compound | |
| GB201411215D0 (en) | Pharmaceutical compound | |
| GB201416462D0 (en) | Compound for use | |
| GB201409405D0 (en) | Therapeutic compounds | |
| GB201406154D0 (en) | Pharmaceutical compound |